Indicated for the treatment of metastatic cancers, often in combination with chemotherapy: 🎗 Metastatic Colorectal Cancer: First and second-line treatment. 🫁 Non-Small Cell Lung Cancer (NSCLC): Specifically non-squamous type. 🧠 Glioblastoma: For recurrent cases. 🥚 Ovarian Cancer: Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Renal Cell Carcinoma (Kidney Cancer).

Dosage and administration

Packaging: 4 ml Vial (Concentration 25 mg/ml = Total 100 mg). ⚠️ ADMINISTRATION & WARNINGS: 💉 IV Infusion Only: Must be diluted in 0.9% Sodium Chloride. DO NOT mix with Dextrose/Glucose solutions. ⏱ Timing: First dose over 90 mins. Subsequent doses may be reduced to 60 or 30 mins if tolerated. 🔪 Surgery Warning: Bevacizumab impairs wound healing. Do not start therapy for at least 28 days following major surgery.

Hypersensitivity to recombinant human or humanized antibodies. Pregnancy and breastfeeding (risk of fetal angiogenetic defects). Untreated CNS metastases (risk of bleeding).

Common adverse events associated with VEGF inhibition: 🩸 Hemorrhage: Most commonly epistaxis (nosebleeds). ⚡ Hypertension: High blood pressure (monitoring required). 🤕 General: Fatigue, asthenia. Wound healing complications. Proteinuria (protein in urine).

Cizumab 100 — Bevacizumab 100 mg / 4 ml, 1 pcs, Hetero

100% original product

Active ingredient

Bevacizumab

Manufacturer

Hetero

Dosage 100 mg / 4 ml

Dosage form Vial

Vials per pack 1

Cizumab 100 (Bevacizumab) 100 mg/4 mL

Name: Cizumab 100
Brand: Hetero
SKU: PROD-109
Price: 4395 UAH
Availability: InStock

4395₴ ~~5186₴~~ -15%

Cizumab 100 (Bevacizumab 100 mg/4 ml) is a targeted antineoplastic agent (Monoclonal Antibody).

Manufacturer: Hetero Healthcare (India). It is a biosimilar to Avastin. Unlike traditional chemotherapy, it targets the tumor's environment rather than the cancer cells directly.

Mechanism of Action ("Starving the Tumor"):

Bevacizumab is an angiogenesis inhibitor. It binds to and neutralizes Vascular Endothelial Growth Factor (VEGF), a protein tumors use to signal the body to grow new blood vessels. By blocking this signal, the drug cuts off the tumor's blood supply, effectively starving it of oxygen and nutrients needed for growth.

✅ Key Benefit: Extends survival and progression-free periods in patients with metastatic cancers.

Indicated for the treatment of metastatic cancers, often in combination with chemotherapy:

🎗 Metastatic Colorectal Cancer: First and second-line treatment.
🫁 Non-Small Cell Lung Cancer (NSCLC): Specifically non-squamous type.
🧠 Glioblastoma: For recurrent cases.
🥚 Ovarian Cancer: Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Renal Cell Carcinoma (Kidney Cancer).

Packaging: 4 ml Vial (Concentration 25 mg/ml = Total 100 mg).

⚠️ ADMINISTRATION & WARNINGS:

💉 IV Infusion Only: Must be diluted in 0.9% Sodium Chloride. DO NOT mix with Dextrose/Glucose solutions.
⏱ Timing: First dose over 90 mins. Subsequent doses may be reduced to 60 or 30 mins if tolerated.
🔪 Surgery Warning: Bevacizumab impairs wound healing. Do not start therapy for at least 28 days following major surgery.

Hypersensitivity to recombinant human or humanized antibodies.
Pregnancy and breastfeeding (risk of fetal angiogenetic defects).
Untreated CNS metastases (risk of bleeding).

Common adverse events associated with VEGF inhibition:

🩸 Hemorrhage: Most commonly epistaxis (nosebleeds).
⚡ Hypertension: High blood pressure (monitoring required).
🤕 General: Fatigue, asthenia.
Wound healing complications.
Proteinuria (protein in urine).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.03.2026